Multidrug Resistant Infections

In 2014, the European Centre for Disease Control described antimicrobial resistance as "a serious threat to public health in Europe, leading to increasing healthcare costs, prolonged hospital stays, treatment failures and deaths".1

Both in the hospital and community setting, the spectrum and frequency of antimicrobial resistant infections has increased over recent years. The emergence of multidrug resistant bacteria can result in limited treatment options for infected patients.

We are committed to providing patients with effective treatment options against multidrug resistant infections, in particular for urinary tract infections and severe respiratory infections.

Click here to view our products

 

1. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2014.

Profile Pharma is a subsidiary of Zambon